Fraudulent ‘Off-Label’ Promotion Claim Against Sandoz Survives Preemption in S.C. Amniodarone Case
April 10, 2017
DOCUMENTS
- Order
FLORENCE, S.C. — A South Carolina federal judge has allowed plaintiffs in an amiodarone action to amend their claim accusing Sandoz Inc. of fraudulently promoting the drug for “off-label” uses, ruling that while the claim is not preempted by federal law, it does not state facts sufficient to establish causation in light of the learned intermediary doctrine.
In a March 31 order, Judge R. Bryan Harwell of the U.S. District Court for the District of South Carolina dismissed with prejudice plaintiff’s claims of failure to warn, design defect, and negligent “off-label” promotion, ruling they are preempted pursuant to Mensing, Bartlett …
FIRM NAMES
- Greenberg Traurig
- Nexsen Pruet Jacobs & Pollard
- Richardson Patrick Westbrook & Brickman
- Wood Law Firm
UPCOMING CONFERENCES
HarrisMartin's Mass Tort Settlements Conference - Sponsored by Milestone
June 27, 2024 - Buffalo, NY
The Richardson Hotel Buffalo
HarrisMartin's MDL Conference: Video Game Addiction and the Latest Mass Tort Updates
May 29, 2024 - Salt Lake City, UT
The Grand America Hotel